Stock data
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX) reported revenue of US$1.30M and net income of -US$140.06M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$1.30M | — | -US$135.03M | -US$140.06M | — |
| 2024 | US$0.20M | — | -US$331.45M | US$1.69B | — |
| 2023 | US$1.80M | — | -US$219.22M | -US$241.36M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$36.65M | — |
| 2026-03-31 | — | -US$33.44M | — |
| 2025-12-31 | US$0.00M | -US$32.83M | — |
| 2025-09-30 | US$0.00M | -US$35.26M | — |
| 2025-06-30 | US$1.30M | -US$28.65M | — |
| 2025-03-31 | US$0.00M | -US$43.31M | — |
| 2024-12-31 | US$0.10M | -US$47.87M | — |
| 2024-09-30 | US$0.00M | -US$43.86M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.